ACR 2022 Tweet by Md Yuzaiful Md Yusof

In the U.S, lupus nephritis affects approximately 40–50% of patients with systemic lupus erythematosus, contributing significantly to the morbidity and mortality of the affected individuals. However, significant differences in clinical approaches to lupus nephritis management still persist.

Professor van Vollenhoven has compiled a state-of-the-art review on lupus treatment advances – current and future. SLE management is entering an unprecedented phase.

Xu et al. from Shanghai University have written an analysis of global lupus nephritis (LN) clinical trials and call for innovation.